Citi released a research report stating that the performance of Sino Biopharmaceutical in the first quarter met expectations, despite sales facing challenges. Management revealed two potential licensing collaborations, both expected to exceed $5 billion in scale. Citi is optimistic about Sino Biopharmaceutical's early-stage R&D pipeline competitiveness and maintains its "highly confident outperform the market" rating, with a target price of HKD 13.8.

Syscoin (SYS) plans to upgrade its Mainnet at Block Height 2010345. Gate.io will suspend the deposit and withdrawal services for SYS tokens during this period, but trading will not be affected. The Gate.io team announced this move in an official message, thanking users for their understanding and support. For more details, please refer to the official link from Gate.io.

Syscoin (SYS) plans to upgrade its mainnet at Block Height 2010345. Gate.io will suspend the deposit and withdrawal services for SYS tokens during this period, but trading will not be affected. The Gate.io team announced this move in an official message, thanking users for their understanding and support. For more details, please refer to the official Gate.io message link.